Medical News

RSS

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

BUSPH, The Partnership at Drugfree.org collaborate to increase 'Join Together' resource utilization

The Partnership at Drugfree.org, in cooperation with the Boston University School of Public Health, announced today that Join Together has become part of the 25-year-old nonprofit organization based in New York City.

4 Apr 2011

Precise Match-on-Card technology achieves quick result in MINEX II evaluation

As the results from the MINEX II test is released, Precise Biometrics emerges with the fastest standardized Match-on-Card technology showing outstanding performance.

4 Apr 2011

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

4 Apr 2011

GLT changes its brand name to Nordson EFD Deutschland

GLT GmbH, a leading distributor of Nordson EFD precision dispensing systems, has been rebranded as Nordson EFD Deutschland.

4 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

AtlantiCare to use MEDai's Risk Navigator solutions for patient management

AtlantiCare, the largest health system in southeastern New Jersey, will allow its healthcare providers to better manage patient populations and track clinical and financial objectives with quality-focused tools from Elsevier/MEDai, a leading provider of predictive analytic solutions.

4 Apr 2011

Oral cancer more common among Americans with HPV16 viral infections

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted.

4 Apr 2011

Cancer Discovery to present practice-changing research at AACR meeting

Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.

4 Apr 2011

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's Annual Meeting

4 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

AACR continues to increase focus on cancer clinical trials

The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year's meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

Catheter Connections presents DualCap device clinical data against CRBSI at SHEA meeting

In the ongoing fight against costly and potentially fatal catheter related bloodstream infections, landmark clinical data presented at the 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America demonstrates that both the exposed end of IV administration sets and catheter luer access valves are colonized by the microbes that cause CRBSI.

4 Apr 2011

Researchers pinpoint effects of enhanced adult neurogenesis in hippocampus

Adult mice engineered to have more newborn neurons in their brain memory hub excelled at accurately discriminating between similar experiences - an ability that declines with normal aging and in some anxiety disorders.

4 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

Techne's R&D Systems acquires Boston Biochem assets

Techne Corporation announced today that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets of Boston Biochem, Inc., a leading developer and manufacturer of innovative ubiquitin-related research products.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011